ProCE Banner Activity

New Evidence With BTK Inhibitor Therapy in CLL and MCL From ASCO 2022

Conference Coverage
Podcast Episodes
Gain insight into expert faculty perspectives as they discuss recent key studies from ASCO 2022 on BTK inhibition in chronic lymphocytic leukemia and mantle cell lymphoma and their potential implications for clinical practice.

Released: July 06, 2022

Expiration: July 05, 2023

Share

Faculty

Brad S. Kahl

Brad S. Kahl, MD

Skoronski Chair of Lymphoma Research
Associate Director for Clinical Research
UW Carbone Cancer Center
University of Wisconsin School of Public Health
Madison, Wisconsin

Anthony Mato

Anthony Mato, MD, MSCE

Associate Professor
Division of Leukemia
Memorial Sloan Kettering Cancer Center
New York, New York

Provided by

Provided by Clinical Care Options, LLC
ProCE Banner

Supporters

Supported by an educational grant from

Lilly

Faculty Disclosure

Primary Author

Brad S. Kahl, MD

Skoronski Chair of Lymphoma Research
Associate Director for Clinical Research
UW Carbone Cancer Center
University of Wisconsin School of Public Health
Madison, Wisconsin

Brad S. Kahl, MD: consultant: AbbVie, AcertaPharma, ADCT Therapeutics, AstraZeneca, Celegene, Genentech, MEI, Morphosys, Pharmacyclics, Roche, TG Therapeutics.

Anthony Mato, MD, MSCE

Associate Professor
Division of Leukemia
Memorial Sloan Kettering Cancer Center
New York, New York

Anthony Mato, MD, MSCE: consultant: AbbVie, Acerta/AstraZeneca, Adaptive, AZ, Celgene, DTRM BioPharma, Genentech, Genmab, Johnson & Johnson, Loxo, Nurix, Pharmacyclics, Sunesis, TG Therapeutics, Verastem; researcher: AbbVie, Acerta/AstraZeneca, Adaptive, DTRM BioPharma, Genmab, Johnson & Johnson, Loxo Oncology, Nurix, Pharmacyclics, Regeneron, Sunesis, TG Therapeutics.